Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... Due to their lower toxicity compared to conventional chemotherapy , hypomethylating agents are often a safe and feasible ... may play a role in epigenetic "priming" before conventional chemotherapy. This review summarizes the results of clinical trials and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

    ... leukemia (AML) unlikely to benefit from cytotoxic chemotherapy . Switching hypomethylating agents after treatment failure is ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Update on the pharmacotherapy for myelodysplastic syndromes

    ... relied upon supportive care and intensive chemotherapy . The last decade has seen many scientific and therapeutic ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents

    ... use of HMAs, add-back strategies, other palliative chemotherapy options, and provide an overview for several promising ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study

    ... received disease-modifying therapies (DMT) that included chemotherapy (CHT) for 65 patients, allogeneic stem-cell transplantation ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia.

    ... studies have identified poor-risk cytogenetics , chemotherapy resistance, comorbidities from prior cancer and therapy, and ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes

    ... elderly patients and those with prior exposure to chemotherapy , radiation, and environmental toxins in the presence of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia

    ... salicylate may be safely combined with conventional chemotherapy regimens which are not associated with significant ototoxicity ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults

    ... hematopoietic growth factors, hypomethylating agents, chemotherapy or transplantation) , progression to acute myeloid leukemia, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies

    ... treatment prior to transplantation, including induction chemotherapy (ICT) alone (ICT group; n = 98), AZA alone (AZA group; n = ...

    Research Article last updated 07/20/2018 - 5:14pm.